

INFLUENZA A INFECTIONS

44. Tang TT, Siegesmund KA, Sedmak GV, et al: Reye syndrome, a correlated electronmicroscopic, viral and biochemical observation. *JAMA* 232:1339-1346, 1975
45. Davidson AM, Thomson D, Robson JS: Intravascular coagulation complicating influenza A virus infection. *Br Med J* 1: 654-655, Mar 1973
46. Whitaker AN, Bunce I: Disseminated intravascular coagulation and acute renal failure in influenza A2 infection. *Med J Aust* 2:196-201, Aug 1974
47. Thein S, Ming K, Thauung U, et al: Haemorrhagic manifestations of influenza A infection in children. *J Trop Med Hyg* 78: 76-80, Apr 1975
48. Myking O, Schreiner A: Influenza virus infection complicated by severe renal failure. *Scand J Infect Dis* 6:205-207, 1974
49. Goodpasture EW: The significance of certain pulmonary lesions in relation to the etiology of influenza. *Am J Med Sci* 158:863-870, 1919
50. Wilson CB, Smith RC: Goodpasture's syndrome associated with influenza A2 virus infection. *Ann Intern Med* 76:91-94, Jan 1972
51. Leading article: Virus and bacteria. *Br Med J* 4:745-746, Dec 1972
52. Eickhoff TC: Sero-epidemiologic studies of meningococcal infection with the indirect hemagglutination test. *J Infect Dis* 123: 519-526, May 1971
53. Young LS, LaForce FM, Head JJ, et al: A simultaneous outbreak of meningococcal and influenza infections. *N Engl J Med* 287:5-9, Jul 1972
54. Reed WP, Olds JW, Kesch AL: Decreased skin-test reactivity associated with influenza. *J Infect Dis* 125:398-402, 1972
55. Kleinerman ES, Synderman R, Daniels CA: Depressed monocyte chemotaxis during acute influenza infection. *Lancet* 2: 1063-1066, Nov 1975
56. Larson HE, Blades R: Impairment of human polymorphonuclear leukocyte function by influenza virus. *Lancet* 1:283, Feb 1976
57. Schlesinger JJ, Ernst C, Weinstein L: Inhibition of human neutrophil chemotaxis by influenza virus. *Lancet* 1:650-651, Mar 1976

Orally Given Hypoglycemic Drugs and Cardiovascular Disease

I feel that we should concede that there is perhaps a relationship between the use of orally given hypoglycemic drugs and cardiovascular disease . . . If we have conceded that there is a possibility of a problem inherent in the use of the oral agents, then I think we are on poor grounds to administer orally given hypoglycemic drugs to these patients . . . There is a problem in giving these patients insulin. One has to be very careful in its administration, simply because one does not want hypoglycemia to occur in patients who are being given insulin or who are receiving any form of therapy. The reason for this is that there is an outpouring of epinephrine in these patients as a response to their hypoglycemic state and even myocardial infarction has been seen on occasion, so one must be very careful in this group of patients.

—STANLEY N. COHEN, MD, *Philadelphia*
 Extracted from *Audio-Digest Internal Medicine*, Vol. 23, No. 6,
 in the Audio-Digest Foundation's subscription series of tape-
 recorded programs. For subscription information: 1930 Wilshire
 Blvd., Suite 700, Los Angeles, CA 90057.